Descrição

Intravenous Immunoglobulin (IVIG) is a therapy treatment for patients with antibody deficiencies. It is prepared from a pool of immunoglobulins (antibodies) from the plasma of thousands of healthy donors. Immunoglobulins are made by the immune system of healthy people for the purpose of fighting infections. According to StrategyHelix, the intravenous immunoglobulin market in United States is expected to increase by US$ 2.5 bilhão durante 2022-2028, expanding at a CAGR of 6.4% durante o período de previsão.

O relatório fornece dados atualizados sobre o tamanho do mercado para o período 2018-2021 e previsão para 2028 covering key market aspects like sales value for intravenous immunoglobulin. The United States intravenous immunoglobulin market is segmented on the basis of application, e usuário final. Based on application, the intravenous immunoglobulin market in United States is categorized into chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, outros. The immunodeficiency diseases segment held the largest share of the United States intravenous immunoglobulin market in 2021 and is anticipated to hold its share during the forecast period. On the basis of end user, the intravenous immunoglobulin market in United States has been segmented into homecare, hospitais & clínicas.

The United States intravenous immunoglobulin market is highly competitive. Key companies profiled in the report include ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited. Competitive landscape gives a description of the competitive nature of the intravenous immunoglobulin market in United States and a description of the leading companies. Os principais negócios financeiros que moldaram o mercado nos últimos anos são identificados.

O relatório é um recurso inestimável para empresas e organizações ativas neste setor. It provides a cohesive picture of the intravenous immunoglobulin market to help drive informed decision making for industry executives, decisores políticos, acadêmico, e analistas.

Escopo do relatório

Aplicativo: chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, outros
Usuário final: homecare, hospitais & clínicas
Anos considerados: este relatório cobre o período 2018 para 2028
Empresa mencionada: ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited

Principais benefícios para as partes interessadas

– Get a comprehensive picture of the United States intravenous immunoglobulin market
– Identificar estratégias regionais e prioridades estratégicas com base em dados locais
– Identifique setores de crescimento e tendências para investimento

Índice

Papel 1. Introdução
– Escopo do estudo
– Período de estudos
– Escopo geográfico
– Metodologia de Pesquisa
Papel 2. Intravenous immunoglobulin market overview
Papel 3. Market breakdown by application
– Chronic inflammatory demyelinating polyneuropathy (CIDP)
– Chronic lymphocytic leukemia
– Congenital HIV/AIDS
– Guillain-barre syndrome (GBS)
– Hypogammaglobulinemia
– Immune thrombocytopenic purpura (ITP)
– Immunodeficiency diseases
– Kawasaki disease
– Multifocal motor neuropathy (MMN)
– Myasthenia gravis
– Outros
Papel 4. Detalhamento do mercado por usuário final
– Homecare
– Hospitais & clínicas
Papel 5. Principais empresas
– ADMA Biologics Inc.
– Biotest AG
– CSL Limited
– Grifols, S.A..
– Johnson & Johnson
– Kedrion Biopharma Inc. (Kedrion SpA)
– LFB S.A.
– Octapharma AG
– Takeda Pharmaceutical Company Limited
Sobre StrategyHelix
Isenção de responsabilidade